D
David A. Wohl
Researcher at University of North Carolina at Chapel Hill
Publications - 240
Citations - 8260
David A. Wohl is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 44, co-authored 199 publications receiving 7039 citations.
Papers
More filters
Journal ArticleDOI
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
Paul E. Sax,David A. Wohl,Michael Yin,Frank A. Post,Edwin DeJesus,Michael S. Saag,Anton Pozniak,Melanie Thompson,Daniel Podzamczer,Jean-Michel Molina,Shinichi Oka,Ellen Koenig,Benoit Trottier,Jaime Andrade-Villanueva,Gordon Crofoot,Joseph M. Custodio,Andrew Plummer,Lijie Zhong,Huyen Cao,Hal Martin,Christian Callebaut,Andrew K. Cheng,Marshall W. Fordyce,Scott McCallister +23 more
TL;DR: Renal and bone effects were significantly reduced in patients given E/C/F/tenofovir alafenamide or E-C-F-tenofavir disoproxil fumarate and the main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the US Food and Drug Adminstration snapshot algorithm and pre-specified renal and bone endpoints at 48 weeks.
Journal ArticleDOI
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax,Edwin DeJesus,Anthony Mills,Andrew R. Zolopa,Calvin J. Cohen,David A. Wohl,Joel E. Gallant,Hui C. Liu,Lijie Zhong,Kitty Yale,Kirsten L. White,Brian P. Kearney,Javier Szwarcberg,Erin Quirk,Andrew K. Cheng +14 more
TL;DR: If regulatory approval is given, EVG/COBI/FTC/TDF would be the only single-tablet, once-daily, integrase-inhibitor-based regimen for initial treatment of HIV infection.
Journal ArticleDOI
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
Jeffrey M. Jacobson,John S. Greenspan,John Spritzler,N Ketter,John L. Fahey,J. B. Jackson,Lawrence Fox,Miriam Chernoff,Albert W. Wu,Laurie A. MacPhail,G J Vasquez,David A. Wohl +11 more
TL;DR: Thalidomide is an effective treatment for aphthous ulceration of the mouth and oropharynx in patients with HIV infection and there were unexpected increases in the plasma concentrations of T NF-alpha and soluble TNF-alpha receptors.
Journal ArticleDOI
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Anthony Mills,Jose R. Arribas,Jaime Andrade-Villanueva,Giovanni DiPerri,Jan van Lunzen,Ellen Koenig,Richard Elion,Matthias Cavassini,Jose V aldez Madruga,Jason Brunetta,David Shamblaw,Edwin DeJesus,Chloe Orkin,David A. Wohl,Indira Brar,Jeffrey L. Stephens,Pierre Marie Girard,Gregory D Huhn,Andrew Plummer,Ya Pei Liu,Andrew K. Cheng,Scott McCallister +21 more
TL;DR: Switching to a tenofovir alafenamide-containing regimen from one containing ten ofovir disoproxil fumarate was non-inferior for maintenance of viral suppression and led to improved bone mineral density and renal function.
Journal ArticleDOI
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
Joel E. Gallant,Adriano Lazzarin,Anthony Mills,Chloe Orkin,Daniel Podzamczer,Pablo Tebas,Pierre Marie Girard,Indira Brar,Eric S. Daar,David A. Wohl,Jürgen K. Rockstroh,Xuelian Wei,Joseph M. Custodio,Kirsten L. White,Hal Martin,Andrew T. A. Cheng,Erin Quirk +16 more
TL;DR: This double-blind, multicentre, active-controlled, randomised controlled non-inferiority trial aimed to assess the efficacy and safety of bictegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination versus co formulated dolutegravIR, abacavir, and lamivudine.